Cis-morpholinone MDM2 Inhibitors for Selective p53 Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are limited in effectively targeting tumors with p53 wildtype or inactivated p53 function, as MDM2 inhibits p53 activity, leading to tumor survival and resistance to therapies.
Innovation Solution
Development of compounds that inhibit the interaction between p53 and MDM2, thereby activating p53 downstream effector genes, which can be used to treat various cancers, including solid and liquid tumors, by blocking MDM2's mechanisms of inhibiting p53 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MDM2 inhibitors are used to activate p53 function in tumors, then tumor growth is reduced and p53 activity is restored, but normal tissues may also be affected by p53 activation leading to potential toxicity
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (Formula I and Formula II) that exhibit selective binding affinity to MDM2 in tumor cells versus normal cells. The compounds contain specific heteroaryl groups, substituted phenyl rings, and functional groups (carboxylic acid, amide, ester) that enable preferential interaction with MDM2-p53 complexes in transformed cells, thereby achieving tumor-selective p53 activation while minimizing effects on normal tissues
2Reliability
If small molecules are designed to bind MDM2 and neutralize its interaction with p53, then p53 downstream effector genes are activated, but the complexity of achieving selective binding and appropriate pharmacokinetics increases
Solution Approach 1:
The patent segments the MDM2 inhibitor molecule into distinct functional domains: a heteroaryl group (pyridyl, pyrimidinyl, triazolyl) for initial binding interaction, a central scaffold (cyclohexyl, piperidine, morpholine) for structural stability, and terminal functional groups (carboxylic acid, amide, ester) for hydrogen bonding and solubility. This segmentation allows systematic optimization of each domain's contribution to MDM2 binding affinity and selectivity
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular weight (200-500 Da), logP (1-4), hydrogen bond donors (1-3), and hydrogen bond acceptors (2-5) across the compound series. These parameter optimizations balance binding affinity with pharmacokinetic properties, achieving effective p53 activation while maintaining appropriate drug-like characteristics for in vivo administration
Data Source
AI summary
The present invention provides MDM2 inhibitor compounds of Formula I, or the pharmaceutically acceptable salts thereof,wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.